SI0950657T1 - Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors - Google Patents

Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors

Info

Publication number
SI0950657T1
SI0950657T1 SI9930650T SI9930650T SI0950657T1 SI 0950657 T1 SI0950657 T1 SI 0950657T1 SI 9930650 T SI9930650 T SI 9930650T SI 9930650 T SI9930650 T SI 9930650T SI 0950657 T1 SI0950657 T1 SI 0950657T1
Authority
SI
Slovenia
Prior art keywords
preparation
spla2 inhibitors
substituted carbazoles
carbazoles
substituted
Prior art date
Application number
SI9930650T
Other languages
English (en)
Slovenian (sl)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Gary Alan Hite
Michael Dean Kinnick
Edward David Mihelich
John Michael Morin Jr.
Daniel Jon Sall
Robert Theodore Vasileff
Original Assignee
Eli Lilly And Comapany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Comapany filed Critical Eli Lilly And Comapany
Publication of SI0950657T1 publication Critical patent/SI0950657T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9930650T 1998-04-17 1999-04-16 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors SI0950657T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
EP99302967A EP0950657B1 (en) 1998-04-17 1999-04-16 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors

Publications (1)

Publication Number Publication Date
SI0950657T1 true SI0950657T1 (en) 2005-02-28

Family

ID=22041763

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930650T SI0950657T1 (en) 1998-04-17 1999-04-16 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors

Country Status (30)

Country Link
EP (2) EP0950657B1 (enExample)
JP (2) JP4435330B2 (enExample)
KR (2) KR100586761B1 (enExample)
CN (1) CN1149193C (enExample)
AR (2) AR018593A1 (enExample)
AT (2) ATE271037T1 (enExample)
AU (2) AU753547B2 (enExample)
BR (2) BR9902365A (enExample)
CA (2) CA2269246C (enExample)
CO (2) CO5031247A1 (enExample)
CZ (2) CZ136999A3 (enExample)
DE (2) DE69917833T2 (enExample)
DK (1) DK0950657T3 (enExample)
DZ (1) DZ2769A1 (enExample)
EA (2) EA002347B1 (enExample)
ES (2) ES2222663T3 (enExample)
HU (2) HUP9901220A3 (enExample)
ID (2) ID23287A (enExample)
IL (2) IL129483A0 (enExample)
NO (2) NO314400B1 (enExample)
NZ (3) NZ507564A (enExample)
PE (2) PE20000476A1 (enExample)
PL (2) PL332566A1 (enExample)
PT (1) PT950657E (enExample)
SG (2) SG81976A1 (enExample)
SI (1) SI0950657T1 (enExample)
TR (2) TR199900843A2 (enExample)
TW (1) TWI238160B (enExample)
YU (2) YU19199A (enExample)
ZA (2) ZA992771B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
CA2719721C (en) 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CN104797559A (zh) * 2012-11-30 2015-07-22 通用电气健康护理有限公司 卤化锌介导的环化过程得到三环吲哚
CN111362863A (zh) 2012-11-30 2020-07-03 通用电气健康护理有限公司 三环吲哚衍生物的结晶方法
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
CA2269246C (en) 2009-08-25
AU753436B2 (en) 2002-10-17
BR9902365A (pt) 2001-04-24
PL332566A1 (en) 1999-10-25
IL129485A0 (en) 2000-02-29
EA199900301A3 (ru) 2000-04-24
YU18999A (sh) 2002-08-12
EA199900303A2 (ru) 1999-10-28
EP0952149A2 (en) 1999-10-27
ATE268756T1 (de) 2004-06-15
NO991822L (no) 1999-10-18
PT950657E (pt) 2004-11-30
CO5031247A1 (es) 2001-04-27
AU753547B2 (en) 2002-10-24
CA2269246A1 (en) 1999-10-17
EP0950657B1 (en) 2004-07-14
HUP9901221A3 (en) 2001-11-28
DE69917833T2 (de) 2005-07-14
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
NO991822D0 (no) 1999-04-16
NZ507564A (en) 2002-10-25
HUP9901220A3 (en) 2001-11-28
PE20000432A1 (es) 2000-05-23
NO991821D0 (no) 1999-04-16
AU2381799A (en) 1999-10-28
PL332565A1 (en) 1999-10-25
JP2000026416A (ja) 2000-01-25
HU9901221A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
CN1149193C (zh) 2004-05-12
DE69917833D1 (de) 2004-07-15
ES2222663T3 (es) 2005-02-01
ATE271037T1 (de) 2004-07-15
JP4435330B2 (ja) 2010-03-17
ES2226286T3 (es) 2005-03-16
EP0952149A3 (en) 2001-08-16
DE69918590T2 (de) 2005-07-21
NO312240B1 (no) 2002-04-15
TR199900853A3 (tr) 1999-11-22
AU2381999A (en) 1999-10-28
IL129483A0 (en) 2000-02-29
EP0952149B1 (en) 2004-06-09
HU9901220A (hu) 2000-04-28
AR018186A1 (es) 2001-10-31
ZA992771B (en) 2002-04-18
EP0950657A2 (en) 1999-10-20
ID23287A (id) 2000-04-05
NZ335251A (en) 2000-11-24
YU19199A (sh) 2002-08-12
DK0950657T3 (da) 2004-11-22
JPH11322713A (ja) 1999-11-24
HU9901220D0 (en) 1999-06-28
ZA992772B (en) 2002-07-16
DE69918590D1 (de) 2004-08-19
TR199900853A2 (xx) 1999-11-22
BR9901279A (pt) 2000-05-02
AR018593A1 (es) 2001-11-28
NO314400B1 (no) 2003-03-17
CZ137099A3 (cs) 1999-11-17
CO5011054A1 (es) 2001-02-28
EA199900301A2 (ru) 1999-10-28
KR19990083232A (ko) 1999-11-25
HU9901221D0 (en) 1999-06-28
TR199900843A2 (xx) 2000-02-21
SG81976A1 (en) 2001-07-24
TWI238160B (en) 2005-08-21
CZ136999A3 (cs) 1999-11-17
PE20000476A1 (es) 2000-06-02
EP0950657A3 (en) 2001-08-16
SG81977A1 (en) 2001-07-24
CA2269262A1 (en) 1999-10-17
DZ2769A1 (fr) 2003-12-01
KR100586761B1 (ko) 2006-06-08
KR19990083233A (ko) 1999-11-25
NO991821L (no) 1999-10-18
EA002347B1 (ru) 2002-04-25
EA199900303A3 (ru) 2000-04-24
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
IL138847A0 (en) New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
AU2001227966A1 (en) Methods for treating tumors
AU6756300A (en) Method for inducing hypothermia
AU2001245283A1 (en) Methods for treating aneurysms
PL346934A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
IL142092A0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
PL344108A1 (en) Process for synthesizing cox-2 inhibitors
AUPP337298A0 (en) Process for microgel preparation
AU2001255602A1 (en) Methods for treating bone tumors
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
HUP0002101A3 (en) Fluoroether compositions, process for producing them and methods for inhibiting their degradation
EG23819A (en) Method for preparing of l-phenylephrine-hydrochloride
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU5638800A (en) High potassium polyphosphate and method for its preparation
IL129906A0 (en) Process for the preparation of beta-isophorone
AU3703499A (en) Substituted indolinones as kinase inhibitors
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
AU2373600A (en) Novel spla2 inhibitors
AU6088799A (en) Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors
AU7798100A (en) Improved method for producing symmetrical anhydrides
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
AU4021700A (en) Methods of use of beta1-integrin inhibitors
HUP0105152A3 (en) Method for treatment of headache
HUP9902745A3 (en) Process for the preparation of benzylcarbazate